Boots UK’s pharmacy revenue decreased by 0.4% for the year ending August 31 2025, the health and beauty giant’s accounts have revealed.
According to the filing, published on June 6, Boots UK’s pharmacy revenue totalled £2.27bn in 2024/25, down from the previous year’s £2.28bn.
But it added that “comparable” pharmacy revenue increased by 5% compared to the same period the year before.
Read more: Boots announces new CEO as Hemmerdinger departs
“Comparable stores” are those that have been “open for at least twelve months without closure for seven or more consecutive days” and “without major remodel or being subject to a natural disaster in the past twelve months”, it noted.
The growth in comparable pharmacy revenue was “mainly driven” by NHS Advanced services such as Pharmacy First and Boots Online Doctor, which the company said “more than offset declines in state-funded income”.
Read more: Boots becomes ‘private standalone’ company following WBA sale
And it noted that its pharmacy revenue “is impacted by quarterly government adjustments to medicine reimbursement prices via the National Drug Tariffs to ensure sector delivery of agreed contractual procurement margin within the year”.
Meanwhile, Boots UK’s overall post-tax profit for 2024/25 was £261m, a £50m increase on the previous year, while its total revenue increased by 3.2% to £7.54bn.
Read more: Boots launches private bone health scan service
Pharmacy made up 30.2% of this total revenue, a slight decrease from the 31.2% reported for 2023/24.
And the company said it operated 1,824 stores as of August 31 2025, down 16 from the same time the year before.
Read more: Pharmacy2U pre-tax losses up 68% despite revenue growth
It comes after Boots announced the departure of current chief executive Anthony Hemmerdinger, who will be replaced by Currys chief executive Alex Baldock in autumn.
And it follows trainee pharmacists at Boots securing a 6% pay uplift in February, following talks between the multiple and the Pharmacists’ Defence Association Union.
